Esketamine counters opioid-induced respiratory depression.

Area of Science:

• Anesthesiology and Pharmacology
• Respiratory Physiology

Background:

• Opioids are known to cause dangerous respiratory depression.
• Understanding countermeasures for opioid-induced respiratory depression is critical.

Purpose of the Study:

• To investigate if esketamine can stimulate breathing in a human model of opioid-induced respiratory depression.
• To determine the mechanism by which esketamine affects respiratory control.

Main Methods:

• A randomized, double-blind, placebo-controlled, crossover study involving 12 healthy volunteers.
• Esketamine infusion was administered on top of remifentanil-induced respiratory depression.
• Population pharmacokinetic-pharmacodynamic analysis was used to assess drug effects.

Main Results:

• Remifentanil reduced ventilation by approximately 40% through effects on baseline ventilation and CO2 sensitivity.
• Esketamine selectively increased breathing by enhancing ventilatory CO2 sensitivity.
• Esketamine's effect was rapid, dose-dependent, and linked to plasma concentrations.

Conclusions:

• Esketamine effectively counteracted remifentanil-induced respiratory depression.
• The primary mechanism involved restoring ventilatory CO2 chemosensitivity.
• Esketamine shows promise as a treatment for opioid-induced respiratory depression.